Clinical Trial Update: A Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP). [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating efgartigimod in adults with immune thrombocytopenia has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• Vyvgart (efgartigimod alfa) (efgartigimod alfa)

Snippet

Sponsor: argenx | Conditions: Primary Immune Thrombocytopenia | Phase 3 | Status: COMPLETED | Results posted: 2025-03-13